Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy.

Dubois C, Martin F, Hassel C, Magnier F, Daumar P, Aubel C, Guerder S, Mounetou E, Penault-Lorca F, Bamdad M.

J Clin Med. 2019 Dec 26;9(1). pii: E64. doi: 10.3390/jcm9010064.

2.

The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines.

Dubois C, Daumar P, Aubel C, Gauthier J, Vidalinc B, Mounetou E, Penault-Llorca F, Bamdad M.

J Clin Med. 2019 Mar 21;8(3). pii: E397. doi: 10.3390/jcm8030397.

3.

Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells.

Daumar P, Dufour R, Dubois C, Penault-Llorca F, Bamdad M, Mounetou E.

J Pharm Biomed Anal. 2018 Apr 15;152:74-80. doi: 10.1016/j.jpba.2018.01.036. Epub 2018 Jan 31.

PMID:
29414021
4.

Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines.

Dubois C, Dufour R, Daumar P, Aubel C, Szczepaniak C, Blavignac C, Mounetou E, Penault-Llorca F, Bamdad M.

Oncotarget. 2017 Aug 24;8(56):95316-95331. doi: 10.18632/oncotarget.20517. eCollection 2017 Nov 10.

5.

BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.

Dufour R, Daumar P, Mounetou E, Aubel C, Kwiatkowski F, Abrial C, Vatoux C, Penault-Llorca F, Bamdad M.

Sci Rep. 2015 Aug 3;5:12670. doi: 10.1038/srep12670.

6.

PEGylation enhances the tumor selectivity of melanoma-targeted conjugates.

André M, Besse S, Chezal JM, Mounetou E.

Org Biomol Chem. 2015 Jan 14;13(2):388-97. doi: 10.1039/c4ob01751j. Epub 2014 Nov 3.

PMID:
25363288
7.

Spacer optimization of new conjugates for a melanoma-selective delivery approach.

André M, Tarrit S, Couret MJ, Galmier MJ, Débiton E, Chezal JM, Mounetou E.

Org Biomol Chem. 2013 Oct 7;11(37):6372-84. doi: 10.1039/c3ob41428k.

PMID:
23959430
8.

New quaternary ammonium oxicam derivatives: synthesis and in vitro antiosteoarthritis evaluation.

Vidal A, Chezal JM, Mounetou E.

Eur J Med Chem. 2010 Jan;45(1):405-10. doi: 10.1016/j.ejmech.2009.09.026. Epub 2009 Sep 16.

PMID:
19818539
9.

N-4-iodophenyl-N'-2-chloroethylurea, a novel potential anticancer agent with colon-specific accumulation: radioiodination and comparative in vivo biodistribution profiles.

Mounetou E, Miot-Noirault E, Gaudreault RC, Madelmont JC.

Invest New Drugs. 2010 Apr;28(2):124-31. doi: 10.1007/s10637-009-9222-z. Epub 2009 Feb 10.

PMID:
19205625
10.

A new O6-alkylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and human-resistant M4Beu melanoma xenograft models.

Rapp M, Maurizis JC, Papon J, Labarre P, Wu TD, Croisy A, Guerquin-Kern JL, Madelmont JC, Mounetou E.

J Pharmacol Exp Ther. 2008 Jul;326(1):171-7. doi: 10.1124/jpet.108.137737. Epub 2008 Apr 14.

PMID:
18411412
11.

Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases.

Vidal A, Sabatini M, Rolland-Valognes G, Renard P, Madelmont JC, Mounetou E.

Bioorg Med Chem. 2007 Mar 15;15(6):2368-74. Epub 2007 Jan 19.

PMID:
17267227
12.

Alkylation of beta-tubulin on Glu 198 by a microtubule disrupter.

Bouchon B, Chambon C, Mounetou E, Papon J, Miot-Noirault E, Gaudreault RC, Madelmont JC, Degoul F.

Mol Pharmacol. 2005 Nov;68(5):1415-22. Epub 2005 Aug 12.

PMID:
16099845
13.

Antineoplastic potency of arylchloroethylurea derivatives in murine colon carcinoma.

Miot-Noirault E, Legault J, Cachin F, Mounetou E, Degoul F, Gaudreault RC, Moins N, Madelmont JC.

Invest New Drugs. 2004 Nov;22(4):369-78.

PMID:
15292707
14.

Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.

Petitclerc E, Deschesnes RG, Côté MF, Marquis C, Janvier R, Lacroix J, Miot-Noirault E, Legault J, Mounetou E, Madelmont JC, C -Gaudreault R.

Cancer Res. 2004 Jul 1;64(13):4654-63.

15.

Supplemental Content

Loading ...
Support Center